Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
WILLOW LABORATORIES via WILLOW LABORATORIES
2026 · third_quarter · Q3
Support for increased Medicare and Medicaid coverage and reimbursement for diabetes prevention technologies
corporate governance and transparency
Source: Senate LDA
Support for coverage and reimbursement for diabetes prevention and wellness technologies; patient safety; support for PBM reform and corporate governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WILLOW LABORATORIES via WILLOW LABORATORIES
2026 · second_quarter · Q2
Support for increased Medicare and Medicaid coverage and reimbursement for diabetes prevention technologies
Support for coverage and reimbursement for diabetes prevention and wellness technologies; patient safety; support for PBM reform and corporate governance.
corporate governance and transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WILLOW LABORATORIES via WILLOW LABORATORIES
2026 · first_quarter · Q1
Support for coverage and reimbursement for diabetes prevention and wellness technologies; patient safety; support for PBM reform and corporate governance.
corporate governance and transparency
Support for increased Medicare and Medicaid coverage and reimbursement for diabetes prevention technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WILLOW LABORATORIES via WILLOW LABORATORIES
2025 · fourth_quarter · 4A
Support for coverage and reimbursement for diabetes prevention and wellness technologies; patient safety; support for PBM reform and corporate governance.
Support for increased Medicare and Medicaid coverage and reimbursement for diabetes prevention technologies
corporate governance and transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WILLOW LABORATORIES via WILLOW LABORATORIES
2025 · fourth_quarter · Q4
Support for coverage and reimbursement for diabetes prevention and wellness technologies; patient safety; support for PBM reform and corporate governance.
Support for increased Medicare and Medicaid coverage and reimbursement for diabetes prevention technologies
corporate governance and transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WILLOW LABORATORIES via WILLOW LABORATORIES
2025 · third_quarter · 3A
Support for funding, coverage and reimbursement for diabetes prevention and wellness technologies; patient safety; support for PBM reform.
Support for increased Medicare and Medicaid coverage and reimbursement for diabetes prevention technologies; support for CMS TEAM Model [CMMI]
corporate governance and transparency
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WILLOW LABORATORIES via WILLOW LABORATORIES
2025 · third_quarter · Q3
Support for funding, coverage and reimbursement for diabetes prevention and wellness technologies; patient safety; support for PBM reform.
Support for increased Medicare and Medicaid coverage and reimbursement for diabetes prevention technologies; support for CMS TEAM Model [CMMI]
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WILLOW LABORATORIES via WILLOW LABORATORIES
2025 · third_quarter · RR
Medicare coverage for diabetes technology patient safety